Everything below concerns somatotroph. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
DavePhos, the first reported dialkylbiaryl phosphine ligand, was initially used in Pd-catalyzed Suzuki-Miyaura cross-coupling reactions as well as Buchwald-Hartwig aminations. Complexes of this ligand also catalyze a wide array of reactions, including the arylation of ketones and esters, borylation of aryl chlorides, and the arylation of indoles. Many modified versions of DavePhos have been synthesized. t-BuDavePhos has been shown to be an even more reactive variant of DavePhos in the room temperature Suzuki-Miyaura coupling of aryl bromides and chlorides. The biphenyl equivalent (PhDavePhos) is also available.
This museum is part of the large historical memorial commemorating victory in the Patriotic War of 1812 over Napoleon's army; this memorial also includes a triumphal arch erected in 1827. In addition, Moscow contains a military history museum containing statues and military hardware. The Memorial Museum of Cosmonautics under the Monument to the Conquerors of Space at the end of Cosmonauts Alley is the central memorial for Russian space officials. The Shchusev State Museum of Architecture is the national museum of Russian architecture, named after the architect Alexey Shchusev. This museum is located near the Kremlin.
Astrocytes (from Ancient Greek ἄστρον, ástron, "star" and κύτος, kútos, "cavity", "cell"), also known collectively as astroglia, are characteristic star-shaped glial cells in the brain and spinal cord. They perform many functions, including biochemical control of endothelial cells that form the blood–brain barrier, provision of nutrients to the nervous tissue, maintenance of extracellular ion balance, regulation of cerebral blood flow, and a role in the repair and scarring process of the brain and spinal cord following infection and traumatic injuries. The proportion of astrocytes in the brain is not well defined; depending on the counting technique used, studies have found that the astrocyte proportion varies by region and ranges from 20% to around 40% of all glia. Another study reports that astrocytes are the most numerous cell type in the brain. Astrocytes are the major source of cholesterol in the central nervous system. Apolipoprotein E transports cholesterol from astrocytes to neurons and other glial cells, regulating cell signaling in the brain. Astrocytes in humans are more than twenty times larger than in rodent brains, and make contact with more than ten times the number of synapses. Research since the mid-1990s has shown that astrocytes propagate intercellular Ca2+ waves over long distances in response to stimulation, and, similar to neurons, release transmitters (called gliotransmitters) in a Ca2+-dependent manner. Data suggest that astrocytes also signal to neurons through Ca2+-dependent release of glutamate.
Although the ancient Egyptians did not always distinguish frankincense from other resins such as myrrh, references to incense from the land of Punt have been dated to the third millennium BCE. Incense trees being transported for cultivation in Thebes are depicted in the so-called "Punt Colonnade" at the mortuary temple of Hatshepsut. The Ebers Papyrus, from around 1500 BCE, provides some of the earliest evidence for frankincense used with intent as a possible therapy. The incense offering occupied a prominent position in the sacrificial legislation of the ancient Hebrews. The Book of Exodus (30:34–38) prescribes frankincense, blended with equal amounts of three aromatic spices, to be ground and burnt in the sacred altar before the Ark of the Covenant in the wilderness Tabernacle, where it was meant to be a holy offering—not to be enjoyed for its fragrance. The Book of Jeremiah (6:20) relates that frankincense was imported from Sheba during the 6th century BC Babylonian captivity. Frankincense is mentioned in the New Testament as one of the three gifts (with gold and myrrh) that the magi "from the East" presented to the Christ Child (Matthew 2:11).
Sources: en.wikipedia.org
Starbucks has faced allegations of anti-union practices in the United States, including allegations of retaliation against employees involved in union organizing. In 2022, over a period of several months, Starbucks terminated more than 85 U.S. workers who had been involved in union organizing. Workers and their union also accused Starbucks of creating a culture of fear and surveillance in its stores. In November 2022, the company announced the closure of a Seattle location that had been the first Starbucks store to unionize in the city, citing safety concerns. In December, workers at more than 100 U.S. stores went on strike over allegations of anti-union practices and working conditions. In December 2024, workers at more than 300 U.S. stores went on strike during the holiday season over stalled contract negotiations concerning wages, staffing, and working conditions. In January 2025, Starbucks and Workers United agreed to use a mediator to help resume stalled negotiations. The union had filed more than 90 unfair labor practice complaints against the company in the preceding weeks. In November 2025, more than 1,000 unionized Starbucks workers in more than 40 U.S. cities began an open-ended strike over stalled contract negotiations. Union organizing and collective bargaining continued into 2026, with Workers United winning representation elections at additional Starbucks locations and new organizing petitions being filed with the National Labor Relations Board.
The Ordre des Palmes académiques (French pronunciation: [ɔʁdʁ de palm(z‿)akademik]; French for 'Order of Academic Palms') is a national order bestowed by the French Republic on distinguished academics and teachers and for valuable service to universities, education and science. Originally established in 1808 by Emperor of the French Napoleon as a decoration to honour eminent members of the University of Paris, it was changed into its current form as an order of merit on 4 October 1955 by President René Coty, making it one of the oldest civil honours bestowed by the French Republic.
=== Ritonavir === Released to the public in 1996, ritonavir is an antiretroviral medication used to help treat HIV/AIDS. It has been listed on the World Health Organization's List of Essential Medicines. The original medication was manufactured in the form of semisolid gel capsules, based on the only known crystal form of the drug ("Form I"). In 1998, however, a second crystal form ("Form II") was unexpectedly discovered. It had significantly lower solubility and was not medically effective. Subsequent research showed that the two forms are conformational polymorphs, with Form II more thermodynamically stable since "all of the strong hydrogen bond donors and acceptors have been satisfied". Form II was of sufficiently lower energy that it became impossible to produce Form I in any laboratory where Form II was introduced, even indirectly. Scientists who had been exposed to Form II in the past seemingly contaminated entire manufacturing plants by their presence, probably because they carried over microscopic seed crystals of the new polymorph. The drug was temporarily recalled from the market. Tens of thousands of AIDS patients went without medication for their condition (unless they switched to a Norvir liquid suspension) until ritonavir was reformulated as a capsule, approved, and re-released to the market in 1999. It is estimated that Abbott, the company which produced ritonavir under the brand name Norvir, lost over US$250 million as a result of the incident.
=== Light chain (AL-CM) === This relatively rare form of cardiac amyloidosis occurs in an estimated six to ten cases per 1,000,000 people. This sub- type usually affects males over the age of 60 and is rapidly progressive. Pathogenesis of this form is due to the aggregation of immunoglobulin lambda light chains. These chains are created by an abnormal expansion of plasma cells. Over time, these light chains deposit into the interstitial tissue within the myocardium. Diagnostic tests includes serum and urine electrophoresis, laboratory testing for the determination of elevated levels of troponin and BNP, and ECGs showing low QRS voltages.
In A&P's traditional grocery stores, "wages and overhead expenses" had consumed 18 percent of sales, while in A&P's newly opened supermarkets in those same neighborhoods, those same numbers were less than 12 percent of sales. Once the large chains joined the supermarket trend, the new retail format exploded across the country like a wildfire. The number of American supermarkets almost tripled from 1,200 in 32 states in 1936 to over 3,000 in 47 states in 1937. It was well over 15,000 by 1950. One sign of the supermarket format's success in slashing labor costs, overhead, and food prices was that the percentage of disposable income spent by American consumers on food plunged "from 21 percent in 1930 to 16 percent in 1940". The modern era of "cheap food" had begun. As large chain stores began to dominate the American grocery landscape with their low overhead and low prices (while crushing numerous independent small stores along the way), a backlash to this radical alteration of food distribution infrastructure appeared in the form of numerous anti-chain campaigns. The idea of "monopsony", proposed by Cambridge economist Joan Robinson in 1933, that a single buyer could outmaneuver a market of multiple sellers, became a strong anti-chain rhetorical device. With public backlash came political pressure to even the playing field for smaller vendors lacking the luxury of economies of scale.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.